RFA-OD-25-008: Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional) — Historical Reference

RFA-OD-25-008: Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional) — Historical Reference

This page is a historical reference for RFA-OD-25-008, the NIH and FDA Tobacco Regulatory Science Small Grant Program for New Investigators. The opportunity is closed. The official NIH notice is marked Expired, its final listed application due date was July 14, 2026, and its expiration date was July 15, 2026. NIH also states that no late applications would be accepted. The Office of Disease Prevention funding listing marks the notice as archived. No replacement R03 announcement is identified on the official Tobacco Regulatory Science Program listings checked for this update.

The page retains 2026-07-14 in its metadata because that is the real closing date of the completed cycle. historicalReference = true signals that the date belongs to an archive entry, not to an open application window. Researchers should not treat this page as permission to submit after the deadline or as evidence that a new round has been announced.

Verified details of the closed notice

The notice also listed an earlier application due date of November 18, 2025. The official NIH Frequently Asked Questions page explains that this date was extended to December 5, 2025 because of the government shutdown. The later July 14, 2026 date is the closed cycle deadline retained by this page.

What the program was designed to support

The notice sought small, self-contained research projects by investigators in the early stages of independent careers in tobacco regulatory research. NIH described the R03 mechanism as suitable for pilot and feasibility studies, secondary analyses of existing data, small research projects, research-method development, and new research technology. Projects were expected to produce evidence that could ultimately inform FDA regulation of tobacco product manufacturing, distribution, or marketing.

The program was not a general public-health grant. A responsive application had to address FDA Center for Tobacco Products regulatory authority and at least one of the High-Priority Research Topics in the notice. The interagency structure mattered: NIH would administer awards using funds made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act. The intended result was new scientific evidence relevant to tobacco-product regulation and public-health protection.

The listed priority areas included addiction, behavior, health effects, product composition and design, and toxicity. The detailed topic language was narrow. Examples included nicotine delivery and abuse liability for specified products, product characteristics and their effects on behavior or health, variability in nicotine pouch characteristics, propylene glycol and microbial growth in specified tobacco products, and in vitro dose-response data relevant to the toxicity of ethyl maltol or maltol in ENDS-related research. A proposal needed to connect its aims to the actual bullets in the notice rather than rely on a broad claim that tobacco research is useful.

The notice defined product characteristics broadly to include materials, ingredients, nicotine formulations and concentrations, flavors, design, composition, heating source, nicotine flux, and harmful or potentially harmful constituents. Packaging was excluded from that definition. Where appropriate, investigators could focus on populations experiencing tobacco-related disparities, but they were expected to explain why the population was important to the research question and how the work related to population health.

Eligibility for the completed cycle

The eligible investigator pool was narrower than the list of eligible organizations. Only New Investigators meeting the notice’s criteria could apply. This included Early-Stage Investigators and investigators who had not successfully competed for independent NIH funding. The notice also described the opportunity as being for people who had not yet received a grant supporting research in tobacco regulatory science.

The notice excluded individuals who had received any NIH Research Project Grant (R01) from an NIH Institute or Center. It also excluded people who had received an FDA CTP-funded Small Grant Program award (R03), an FDA CTP-funded Exploratory/Developmental Research Grant award (R21), or the Research Award Phase of an FDA CTP-funded Pathway to Independence award (R00). Those exclusions applied to the individual investigator, not merely to the organization.

Eligible organizations included public and private higher-education institutions; nonprofits with or without 501(c)(3) status; small businesses and other for-profit organizations; state, county, city, township, special-district, federal, and tribal governments; U.S. territories and possessions; independent school districts; public housing authorities; Native American tribal organizations; faith-based or community-based organizations; and regional organizations. Non-U.S. organizations could not apply. Non-U.S. components of U.S. organizations and foreign components, as defined by NIH policy, were also not allowed.

Applicant organizations had to complete and maintain the required registrations before submission. The notice named the System for Award Management, including a Unique Entity Identifier; eRA Commons; and Grants.gov. Each Program Director or Principal Investigator needed an eRA Commons account, and an applicant organization needed the appropriate signing-official and investigator accounts. These were prerequisites for the closed cycle, not a route around the expired deadline.

The opportunity did not require cost sharing. Organizations could submit more than one application if each application was scientifically distinct, but NIH would not accept duplicate or highly overlapping applications under review at the same time.

Budget and project design

Application budgets were limited to $75,000 in direct costs per year, and the maximum project period was two years. NIH, with FDA CTP support, intended to fund up to 4 R03s, corresponding to up to $500,000 for fiscal year 2026. The notice cautioned that future-year amounts would depend on the availability of funds. Those figures describe the completed notice; they are not a commitment for a future round.

The scale called for a discrete and feasible project. A strong application would have selected one well-defined regulatory evidence gap, explained the measurement or analytic approach, and shown how the work could be completed within the R03 period and budget. Pilot work, secondary analysis, methods development, and small technology projects were all plausible, but a large program of loosely connected aims would have been difficult to justify under this mechanism.

Clinical trials were optional. An applicant could propose a clinical trial or a project with no clinical trial, but either design still had to satisfy the topic and regulatory-scope requirements. Human-subjects work required the applicable NIH forms, protections, and study records. Research that generated scientific data had to include a Data Management and Sharing Plan, regardless of the amount of direct costs requested in a year.

The notice also warned applicants to consider tobacco-industry funding and consulting relationships. It pointed to National Advisory Council on Drug Abuse guidance about sponsored research agreements with tobacco companies or related entities. That consideration was relevant to credibility and reputation for applications submitted under the interagency program.

Application steps for the closed cycle

There is no active application route for this notice. The following records the process that applied before the deadline so that the archive remains useful without implying that a late submission is possible.

1. Check responsiveness before drafting the full package. The notice strongly encouraged applicants to discuss proposed aims with an NIH Scientific/Research Contact. NIH’s related Notice of Information asked applicants to request pre-application consultation and to send a draft Specific Aims page to the Tobacco Regulatory Science Program no later than May 14, 2026. Each aim needed to fall within FDA CTP authority and address one or more listed High-Priority Research Topics. A nonresponsive application could be withdrawn before peer review.
2. Confirm the investigator and organization rules. The team had to verify New Investigator status, the R01 and FDA CTP award exclusions, U.S. organizational eligibility, required registrations, and the absence of disqualifying foreign components.
3. Build the application under the Research instructions. NIH required applicants to follow the Research (R) Instructions in the How to Apply—Application Guide, along with the program-specific requirements in the notice. NIH stated that conformance was strictly enforced and that noncompliant applications could be delayed or not accepted for review.
4. Prepare the required forms and plans. Applicants used the SF424 (R&R) forms and one of the permitted electronic routes: NIH ASSIST, an institutional system-to-system solution, or Grants.gov Workspace with eRA Commons tracking. Depending on the project, the package included human-subjects or clinical-trial information, a Data Management and Sharing Plan, resource-sharing information, budget details, and required registrations.
5. Submit electronically and check the application record. The organization had to submit through Grants.gov and complete the tracking process in eRA Commons. Errors had to be corrected by the due date. Applicants were responsible for viewing the application in eRA Commons before the deadline and for ensuring that the PD/PI Commons ID and organizational identifiers matched the registration records.
6. Meet the final deadline. The last listed deadline was July 14, 2026, at 5:00 PM local time of the applicant organization. NIH explicitly said that late applications would not be accepted. The notice has now expired.

The related consultation notice also asked applicants to notify the Tobacco Regulatory Science Program by email when an application had been submitted, including the NOFO number, title, PD/PI name, and application title. That instruction belonged to the closed submission process and should not be read as an invitation to submit after expiration.

Review and fit considerations

NIH described three main review factors: importance of the research, rigor and feasibility, and expertise and resources. Reviewers were asked to consider whether the project addressed an important gap, whether the design could produce unbiased and reproducible data, whether the sample and analysis plan were justified, and whether the investigators and environment could complete the work. For an R03, the project needed to be realistic within two years and within limited funding.

Responsiveness was a threshold issue. Applications that were outside FDA CTP regulatory authority or did not address the listed High-Priority Research Topics would not be reviewed. The notice specifically called nonresponsive a number of areas, including tobacco products not explicitly specified in the topics; media or digital-media communication studies; studies of marketing effects on initiation, switching, dual use, or cessation; studies of the effects of FDA regulatory actions; mechanistic studies without a predictive biomarker-of-harm outcome; short-term studies of acute reduced-nicotine cigarette effects; secondary and tertiary exposure biomarkers; in-utero exposure and later behavioral effects; neuroimaging as an exposure or dependence biomarker; and epigenetic biomarker studies.

That list means a proposal could be scientifically strong and still be a poor fit. The project had to explain the regulatory question, identify the exact priority-topic connection, define measurable outputs, and show why the design was achievable at R03 scale. The strongest application materials would have made that connection visible in the Specific Aims, approach, analysis plan, and expected contribution to FDA CTP evidence needs.

What to do after the cycle closed

This opportunity cannot accept a new application now. Researchers interested in tobacco regulatory science should use the archived notice to understand its former scope, then check the active NIH Guide and current Tobacco Regulatory Science Program pages for a different or replacement opportunity. The official listings checked for this update identify RFA-OD-25-008 as archived and do not identify a successor R03 deadline.

Do not carry the $75,000 annual direct-cost limit, two-year period, investigator exclusions, high-priority topics, consultation process, or submission routes into a future application without verifying the new notice. A later announcement could change the participating NIH components, product-specific research topics, award budget, eligibility rules, or application dates.

Official sources

• NIH RFA-OD-25-008 notice
• NIH Notice of Information NOT-OD-26-045
• NIH Tobacco Regulatory Science Program
• NIH Office of Disease Prevention funding archive